These data suggest that the combination of hypoxia-activated chemotherapy and blockade of VEGFR-2 signaling effectively combats both pancreatic and prostate tumors but does so without engaging or promoting enhanced adaptive antitumor immunity. The gene discussed is KDR; the disease is prostate neoplasm.